Rho-kinase inhibition prevents proteinuria in immune-complex-mediated antipodocyte nephritis

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 7, 2012, Pages

  Meyer Schwesinger, Catherine ^a   Dehde, Silke ^b   Sachs, Marlies ^a   Mathey, Sabrina ^a   Arefi, Kazem ^a   Gatzemeier, Stefan ^a   Balabanov, Stefan ^a   Becker, Jan U ^c   Thaiss, Friedrich ^a   Meyer, Tobias N ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d University Affiliated Hospital Hamburg Barmbek   (Germany)

Author keywords

Fasudil (HA 1077); Immune complex glomerulonephritis; Mouse model; Podocyte injury; Proteinuria; Rho kinase activity

Indexed keywords

BETA ACTIN; FASUDIL; NEPHRIN; POLYCLONAL ANTIBODY; RHO KINASE; RHO KINASE INHIBITOR; SYNAPTOPODIN;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPODOCYTE NEPHRITIS; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOSKELETON; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVITY; GLOMERULUS FILTRATION; HEYMANN NEPHRITIS; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

EID: 84867126616     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00380.2011     Document Type: Article

References (49)

1. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rhokinase. Science 275: 1308-1311., 1997.
2. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rhoassociated kinase. Exp Cell Res 261: 44-51., 2000.
3. Arrondel C, Vodovar N, Knebelmann B, Grunfeld JP, Gubler MC, Antignac C, Heidet L. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 13: 65-74, 2002.
4. Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 7: 255-259, 2003.
5. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, Mundel P. Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 8: 485-491, 2006.
6. Attias O, Jiang R, Aoudjit L, Kawachi H, Takano T. Rac1 contributes to actin organization in glomerular podocytes. Nephron Exp Nephrol 114: e93-e106, 2010.
7. Chang L, Chiang SH, Saltiel AR. TC10alpha is required for insulinstimulated glucose uptake in adipocytes. Endocrinology 148: 27-33, 2007.
8. Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 111: p9-p15, 2009.
9. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
10. Deng B, Yang X, Zhu Z, Zhang C. A Rho-kinase inhibitor, fasudil, attenuates progressive glomerulosclerosis induced by daunorubicin in rats. J Huazhong Univ Sci Technolog Med Sci 29: 720-724, 2009.
11. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 320: 89-98, 2007.
12. Drenckhahn D, Franke RP. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest 59: 673-682, 1988.
13. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12: 413-422, 2001.
14. Gao SY, Li CY, Chen J, Pan L, Saito S, Terashita T, Saito K, Miyawaki K, Shigemoto K, Mominoki K, Matsuda S, Kobayashi N. Rho-ROCK signal pathway regulates microtubule-based process formation of cultured podocytes-inhibition of ROCK promoted process elongation. Nephron Exp Nephrol 97: e49-e61, 2004.
15. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 568: 242-247, 2007.
16. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci 67: 171-177, 2010.
17. Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, Kobler S, Wiech T, Grahammer F, Arnold SJ, Lindenmeyer MT, Cohen CD, Pavenstadt H, Kerjaschki D, Mizushima N, Shaw AS, Walz G, Huber TB. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 120: 1084-1096, 2010.
18. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, Saruta T. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J Pharm Sci 100: 29-33, 2006.
19. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 64: 2009-2019, 2003.
20. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192, 2008.
21. Kentrup D, Reuter S, Schnockel U, Grabner A, Edemir B, Pavenstadt H, Schober O, Schafers M, Schlatter E, Bussemaker E. Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in rat renal acute ischemia-reperfusion injury. PLos One 6: e26419, 2011.
22. Kobayashi N, Gao SY, Chen J, Saito K, Miyawaki K, Li CY, Pan L, Saito S, Terashita T, Matsuda S. Process formation of the renal glomerular podocyte: is there common molecular machinery for processes of podocytes and neurons? Anat Sci Int 79: 1-10, 2004.
23. Komers R, Oyama TT, Beard DR, Tikellis C, Xu B, Lotspeich DF, Anderson S. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int 79: 432-442, 2011.
24. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175-1184, 2008.
25. Meyer TN, Schwesinger C, Wahlefeld J, Dehde S, Kerjaschki D, Becker JU, Stahl RA, Thaiss F. A new mouse model of immunemediated podocyte injury. Kidney Int 72: 841-852, 2007.
26. Meyer-Schwesinger C, Dehde S, Klug P, Becker JU, Mathey S, Arefi K, Balabanov S, Venz S, Endlich K, Pekna M, Gesser E, Thaiss F, Meyer TN. Nephrotic syndrome and subepithelial deposits in a mouse model of immune-mediated anti-podocyte glomerulonephritis. J Immunol 187: 3218-3229, 2011.
27. Meyer-Schwesinger C, Dehde S, von Ruffer C, Gatzemeier S, Klug P, Wenzel UO, Stahl RA, Thaiss F, Meyer TN. Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NFB p65 signaling. Am J Physiol Renal Physiol 296: F1088-F1099, 2009.
28. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 77: 571-580, 2010.
29. Musante L, Candiano G, Bruschi M, Santucci L, Carnemolla B, Orecchia P, Giampuzzi M, Zennaro C, Sanna-Cherchi S, Carraro M, Oleggini R, Camussi G, Perfumo F, Ghiggeri GM. Circulating antiactin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome. Clin Exp Immunol 141: 491-499, 2005.
30. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61: 1684-1695, 2002.
31. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 278: C57-C65, 2000.
32. Niggli V. Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett 445: 69-72, 1999.
33. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, Ono H, Matsuoka H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 25: 1053-1063, 2007.
34. Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, Furthmayr H, Farquhar MG. The glomerular epithelial cell antiadhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol 12: 1589-1598, 2001.
35. Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS, Polasek O, Kolcic I, Biloglav Z, Campbell S, Hastie N, Lauc G, Meitinger T, Oostra BA, Gyllensten U, Wilson JF, Pichler I, Hicks AA, Campbell H, Wright AF, Rudan I, van Duijn CM, Riegler P, Marroni F, Pramstaller PP. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int 76: 297-306, 2009.
36. Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 2008.
37. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456, 2003.
38. Ronco P, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15: 258-263, 2006.
39. Ruperez M, Sanchez-Lopez E, Blanco-Colio LM, Esteban V, Rodriguez-Vita J, Plaza JJ, Egido J, Ruiz-Ortega M. The Rho-kinase pathway regulates angiotensin II-induced renal damage. Kidney Int Suppl 99: S39-45, 2005.
40. Saito H, Minamiya Y, Saito S, Ogawa J. Endothelial Rho and Rho kinase regulate neutrophil migration via endothelial myosin light chain phosphorylation. J Leukoc Biol 72: 829-836, 2002.
41. Salant DJ, Cybulsky AV. Experimental glomerulonephritis. Methods Enzymol 162: 421-461.
42. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-()-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 93: 225-232, 2002.
43. Schmandke A, Schmandke A, Strittmatter SM. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist 13: 454-469, 2007.
44. Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet 24: 333-335, 2000.
45. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y, Betsholtz C. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799-805, 2002.
46. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994, 1997.
47. Wang L, Ellis MJ, Fields TA, Howell DN, Spurney RF. Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis. Kidney Blood Press Res 31: 111-121, 2008.
48. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63, 2008.
49. Zhao Z, Weinstein E, Tuzova M, Davidson A, Mundel P, Marambio P, Putterman C. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 52: 522-530, 2005.